Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
CAR-T vs Bispecifics — Which Performs Better in Myeloma After Initial BCMA Therapy Fails? | #EHA2026
HealthTreeDescription
What happens when multiple myeloma returns after treatment with a BCMA-targeted therapy? At EHA 2026, Dr. Shebli Atrash presented new real-world data comparing outcomes of CAR-T cell therapy versus BCMA-targeted bispecific antibodies in patients who had already received prior BCMA-directed treatment.
This study looked at an important clinical question: Can patients still benefit from another BCMA-targeted approach after BCMA exposure?
If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu
For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!
Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.